Reduced vs standard GVHD prevention in stem cell transplant
Part of Immune system & allergy clinical trials.
This trial tests whether a lower dose of a common drug (cyclophosphamide) after transplant can prevent graft-versus-host disease (a complication where donor cells attack your body) just as well as the standard dose. It also uses another medicine (anti-thymocyte globulin) after the transplant to help protect you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are getting a stem cell transplant from a matched unrelated donor or a half-matched (haplo-identical) donor.
- Your kidneys, liver, lungs, and heart are working normally.
- You are able to care for yourself and do light activities (ECOG score 0-2).
- You are expected to live at least 3 more months.
- You are not pregnant, and you do not have active hepatitis B, active infections needing antibiotics, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
This trial tests a new drug, BPC2001, to see if it can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) in people receiving a half-matched stem cell transplant from a family donor. It may be an option for adults with certain blood cancers who are planning their first transplant.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This trial tests a combination of medications given before and after a stem cell transplant from a family member to prevent graft-versus-host disease (GVHD)—a condition where the new cells attack your body. The study includes a newer drug called ivarmacitinib that may help reduce this serious side effect.
This trial tests a new combination of medicines to prevent graft-versus-host disease (GVHD) in patients with leukemia or myelodysplastic syndromes receiving a stem cell transplant from a half-matched donor. It aims to see if using less anti-thymocyte globulin (ATG) plus a simpler post-transplant cyclophosphamide (PTCy) regimen works as well as standard care with fewer side effects.
Hear when a new Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.